Navigation Links
Skinvisible Offers 8 Hour Photostablity for Parsol 1789
Date:7/29/2008

UVA Sunscreen with Invisicare Available For International Licensing

LAS VEGAS, July 29 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI)(http://www.skinvisible.com, http://www.invisicare.com), the developers of Invisicare, a patented polymer delivery system that enhances topical skincare products, announces the successful development of a new broad spectrum sunscreen combining the active ingredient avobenzone (Parsol(R) 1789) with Invisicare. Avobenzone is one of only two UVA (320-400 nm) sunscreens approved in the USA. It is on the FDA's Category I sunscreen list, as it offers broad-range UVA protection and helps protect the skin against the harmful effects of sun which can cause skin cancers and premature skin aging.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20040503/INVISICARELOGO)

"The results of the studies for our SPF 30 and 50 sunscreens are very impressive," said James Roszell, PhD for Skinvisible Pharmaceuticals. "Avobenzone is notoriously unstable when exposed to light with most products only offering two to four hours of protection. Skinvisible's sunscreens with Invisicare achieved eight hours of photostability with minimal degradation. Additionally, Invisicare has the ability to hold ingredients like avobenzone on the skin for extended periods of time, while resisting wash-off and perspiration; rating our sunscreen formulas as "very water-resistant".

"The completions of our studies are timely as the FDA reviews new labeling standards," said Mr. Terry Howlett, President and CEO of Skinvisible. "The FDA proposed changes to sunscreen labeling so that consumers can easily identify which sunscreen products offer UVA and UVB protection and at what level. This four-star ranking of UVA protection levels ranges from "low," "medium," "high" to "highest". We foresee that Skinvisible's new broad spectrum sunscreen would achieve the "highest" rating."

In addition to sunscreens, Skinvisible has a portfolio of 25 topical dermatology products formulated with Invisicare available for world-wide licensing. In addition to developing proprietary products for clients, Skinvisible's formulations include prescription, over-the-counter and cosmetic products for the treatment of acne, atopic dermatitis, fungal infections, as well as anti-inflammatories, analgesics, hand sanitizers, anti-aging, and sunless tanning products.

Parsol(R) 1789 -- registered trademark of DSM Nutritional Products.

About Invisicare(R) -- Invisicare is Skinvisible's patented polymer delivery system that offers "life-cycle management" and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash-off and perspiration. Invisicare controls the release of actives, reducing irritation and eliminating some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants. http://www.invisicare.com

About Skinvisible Pharmaceuticals, Inc. -- Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare(R) to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development, license, and royalties fees for the life of the Invisicare patent. http://www.skinvisible.com

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending March 30, 2008)

Corporate Contact:

Doreen McMorran, VP Business Development

Skinvisible Pharmaceuticals, Inc

Phone: 702-433-7154

Email: info@skinvisible.com


'/>"/>
SOURCE Skinvisible, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Skinvisible Appoints New Vice President of Business Development & Marketing
2. Skinvisible Signs Licensing Agreement for Two Acne Formulations
3. Skinvisible Appoints New Board Member
4. Skinvisible Announces Licensing Agreement for Adapalene
5. Skinvisible Signs Marketing Agreement for India
6. Skinvisible Appoints Dr. George Korkos to Its Advisory Board
7. Skinvisible to Present at Merriman Curhan Ford & Co.s Investor Summit 2007
8. Geneva Offers First Cardiovascular Technology Graduate Program in the Nation
9. Automated, Wearable Kidney Offers Continuous Dialysis
10. Fairhope Vintners Offers First Release of Classically Styled Napa Valley Cabernet Sauvignon Wines
11. Vinson Hall Retirement Community Offers Glimpse into the Future of Retirement with Unique Innovative Model of Living
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Washington, DC (PRWEB) , ... April 28, 2017 ... ... Unplanned Pregnancy (The National Campaign) announces its support for the Access to ... by Sen. Jeanne Shaheen (D-NH) and Rep. Jackie Speier (D-CA), will help to ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce its ... has been in place since the RBMA was founded in 1968 with all board ... Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for Clinical ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... ... cardiac or hERG liability could substantially improve drug safety and minimize the cost ... provided for validating ion channel inhibition using cell lines and for cardiac toxicity ...
(Date:4/28/2017)... UTAH (PRWEB) , ... April 28, 2017 , ... ... Account Manager for the North East region. Côté has 20+ years of experience ... Prior to Phytomer, Côté worked with an array of high-end cosmetic brands, retail ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Manufacturing Services Market Analysis By Service (Manufacturing, Research), By Country, ... - 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing ... 2025 Low drug registration cost in Latin American ...
(Date:4/19/2017)... 19, 2017 The Mobile X-Ray product segment is ... CAGR during the forecast period Mobile X-Ray segment ... digital mobile X-Ray devices market, which is estimated to be ... at a CAGR of 7% over the forecast period. Mobile ... more than US$ 100 Mn in 2017 over 2016. The ...
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
Breaking Medicine Technology: